Patents by Inventor BENJAMIN ROSSI

BENJAMIN ROSSI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20250236678
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: January 17, 2025
    Publication date: July 24, 2025
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • MULTISPECIFIC NK ENGAGER PROTEIN
    Publication number: 20250215107
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: January 6, 2025
    Publication date: July 3, 2025
    Inventors: Laurent GAUTHIER, Nadia ANCERIZ, Ariane MOREL, Benjamin ROSSI
  • Multispecific NK engager protein
    Patent number: 12252543
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: March 18, 2025
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • Nucleic acids encoding and methods of producing proteins comprising antibody chains
    Patent number: 12202907
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: January 21, 2025
    Assignees: Innate Pharma, Orega Biotech
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • MULTISPECIFIC ANTIBODIES BINDING TO CD20, NKP46, CD16 AND CONJUGATED TO IL-2
    Publication number: 20250002601
    Abstract: The present invention relates to multispecific protein that binds to human NKp46, human CD20, human CD122, and optionally human CD16A. The protein according to the invention have utility in the treatment of disease, such as cancer.
    Type: Application
    Filed: June 8, 2022
    Publication date: January 2, 2025
    Inventors: LAURENT GAUTHIER, YANNIS MOREL, OLIVIER DEMARIA, BENJAMIN ROSSI
  • TREATMENT OF CANCER
    Publication number: 20240325557
    Abstract: The invention relates to antigen-binding proteins capable of binding to Nectin-4 polypeptides conjugated to chemotherapeutic agents, for use in increasing sensitivity of tumors to the chemotherapeutic agents and for use in the treatment of cancers characterized by Nectin-4-expressing tumor cells.
    Type: Application
    Filed: November 24, 2021
    Publication date: October 3, 2024
    Inventors: MANEL KRAIEM, STÉPHANIE CHANTEUX, BENJAMIN ROSSI
  • TREATMENT OF CANCER WITH ILT-2 INHIBITORS
    Publication number: 20240294634
    Abstract: This invention relates to the use of a NKG2A-neutralizing agent and an antibody that inhibits human ILT2 to treat cancer, particularly a head and neck squamous cell carcinoma (HNSCC), a lung cancer, optionally an NSCLC, a renal cell carcinoma, a colorectal carcinoma, a urothelial cancer or an ovarian cancer.
    Type: Application
    Filed: October 13, 2020
    Publication date: September 5, 2024
    Inventors: OLIVIER BENAC, STÉPHANIE CHANTEUX, IVAN PERROT, BENJAMIN ROSSI, NICOLAS VIAUD
  • VARIABLE REGIONS FOR NKP46 BINDING PROTEINS
    Publication number: 20240174748
    Abstract: The application pertains to NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: February 5, 2024
    Publication date: May 30, 2024
    Inventors: LAURENT GAUTHIER, NADIA ANCERIZ, ARIANE MOREL, BENJAMIN ROSSI
  • MULTISPECIFIC NKp46 BINDING PROTEINS
    Publication number: 20240141042
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infections disease.
    Type: Application
    Filed: October 20, 2023
    Publication date: May 2, 2024
    Inventors: Laurent GAUTHIER, Nadia ANCERIZ, Ariane MOREL, Benjamin ROSSI
  • KIR3DL2 BINDING AGENTS
    Publication number: 20240124579
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Application
    Filed: December 27, 2023
    Publication date: April 18, 2024
    Inventors: LAURENT GAUTHIER, SIMON KOLLNBERGER, BENJAMIN ROSSI, HÉLÈNE SICARD, CARINE PATUREL, STÉPHANIE CORNEN, STÉPHANIE ZERBIB
  • IMMUNOHISTOCHEMISTRY METHODS AND KIR3DL2-SPECIFIC REAGENTS
    Publication number: 20240117042
    Abstract: The present invention relates to antibodies and methods for detecting KIR3DL2 expression in paraffin-embedded tissue samples. Also provide are methods of making antibodies, antibody fragments, and derivatives thereof that specifically bind to their target antigen in paraffin-embedded tissue samples.
    Type: Application
    Filed: April 4, 2022
    Publication date: April 11, 2024
    Inventors: BENJAMIN ROSSI, STÉPHANIE CHANTEUX, ROMAIN REMARK, CÉCILE BONNAFOUS, CLARENCE DEFFAUD, THIBAUT PELAT
  • Variable regions for NKp46 binding proteins
    Patent number: 11891444
    Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: February 6, 2024
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • KIR3DL2 binding agents
    Patent number: 11858990
    Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: January 2, 2024
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Simon Kollnberger, Benjamin Rossi, Hélène Sicard, Carine Paturel, Stéphanie Cornen, Stéphanie Zerbib
  • NKp46 binding proteins
    Patent number: 11845795
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 19, 2023
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230340143
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: February 13, 2023
    Publication date: October 26, 2023
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Siglec-9-neutralizing antibodies
    Patent number: 11623954
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: April 11, 2023
    Assignee: INNATE PHARMA
    Inventors: Stéphanie Cornen, Benjamin Rossi, Nicolai Wagtmann, Laurent Gauthier
  • RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXIS
    Publication number: 20230099801
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
    Type: Application
    Filed: July 28, 2022
    Publication date: March 30, 2023
    Inventors: Stéphanie CHANTEUX, Nicolas GOURDIN, Carine PATUREL, Ivan PERROT, Benjamin ROSSI
  • COMBINATION THERAPY USING ANTIBODY TO HUMAN SIGLEC-9 AND ANTIBODY TO HUMAN NKG2A FOR TREATING CANCER
    Publication number: 20230085847
    Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
    Type: Application
    Filed: September 19, 2022
    Publication date: March 23, 2023
    Inventors: STÉPHANIE CORNEN, BENJAMIN ROSSI, NICOLAI WAGTMANN
  • Compositions and methods for treating cancer
    Patent number: 11578136
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 14, 2023
    Assignees: INNATE PHARMA, OREGA BIOTECH
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230025732
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi